--- title: "Hong Kong Stock Movement: AB&B BIO-TECH-B fell 17.78%, vaccine cooperation agreement raises profit concerns, market competition intensifies!" type: "News" locale: "en" url: "https://longbridge.com/en/news/279376882.md" description: "AB&B BIO-TECH-B fell 17.78%; CanSino Biologics rose 1.20%, with a transaction volume of HKD 710 million; Innovent Biologics fell 0.12%, with a transaction volume of HKD 698 million; 3SBio rose 4.01%, with a transaction volume of HKD 658 million; BeiGene fell 0.63%, with a market capitalization of HKD 267.7 billion" datetime: "2026-03-17T06:16:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279376882.md) - [en](https://longbridge.com/en/news/279376882.md) - [zh-HK](https://longbridge.com/zh-HK/news/279376882.md) --- # Hong Kong Stock Movement: AB&B BIO-TECH-B fell 17.78%, vaccine cooperation agreement raises profit concerns, market competition intensifies! **Hong Kong Stock Movement** AB&B BIO-TECH-B fell 17.78%. Based on recent key news: 1. On March 16, AB&B BIO-TECH-B reached an overseas vaccine cooperation agreement with Watson Hong Kong, causing the stock price to drop by 13%. This agreement raised market concerns about the company's future profitability, leading to a significant decline in stock price. The competition in the vaccine industry has intensified, and market volatility is evident. **Stocks with High Trading Volume in the Industry** Kangfang Biotech rose 1.20%. Based on recent key news: 1. On March 16, Kangfang Biotech's trispecific antibody AK150 received clinical trial approval from the National Medical Products Administration. This approval allows clinical trials to be conducted in patients with advanced solid tumors, driving the stock price up. 2. On March 16, the Hong Kong stock market experienced overall fluctuations due to geopolitical conflicts, but southbound funds continued to flow in, providing financial support for the Hong Kong stock market and boosting Kangfang Biotech's stock price. 3. On March 16, the profitability characteristics of the innovative drug industry were emphasized, with some leading companies already achieving profitability. The market holds an optimistic view on the long-term prospects of this sector, driving related stocks up. Significant capital inflow into the Hong Kong stock market has intensified industry volatility. Innovent Biologics fell 0.12%. Based on recent key news: 1. On March 17, CMB International pointed out that the MSCI China Healthcare Index has risen 0.6% year-to-date, outperforming the MSCI China Index by 3.5%. The innovative drug sector has seen a recovery in risk appetite under the policy catalyst of the government work report listing biomedicine as an emerging pillar industry. Innovent Biologics is recommended for purchase, with a target price of 110.62 yuan. 2. On March 16, Yicai reported that despite disturbances from geopolitical conflicts, the Hong Kong stock market still shows structural opportunities supported by significant net inflows of southbound funds. As a leading company in the innovative drug sector, Innovent Biologics benefits from the overall positive trend in the industry. 3. On March 16, Yicai analyzed that the innovative drug industry faces disruptive impacts from AI technology, and some fund managers remain cautious about the sector's trends, planning to observe changes in the underlying valuation logic of the industry. The Hong Kong stock market is supported by southbound funds, increasing volatility. 3SBio rose 4.01%. Based on recent key news: 1. On March 16, 3SBio deepened cooperation with BWH and Dr. Peter Sage, aiming to advance the Phase I clinical trial of gene-modified Treg cell therapy by 2027. Innovative clinical design and AI-enabled tools will promote the treatment of autoimmune diseases, enhancing market confidence and driving the stock price up. Source: Taibao Biomedical 2. On March 16, southbound funds continued to flow into the Hong Kong stock market, with a cumulative net inflow exceeding 180 billion yuan this year, becoming an important support for the Hong Kong stock market and driving up stocks like 3SBio. Source: Yicai 3. On March 17, the government work report listed biomedicine as an emerging pillar industry, and under the policy catalyst, the risk appetite for the sector has recovered. 3SBio benefits from policy dividends, leading to an increase in stock price. Source: CMB International Significant capital inflow into the Hong Kong stock market has intensified volatility **Stocks Ranked Among the Top by Market Capitalization in the Industry** BeiGene fell by 0.63%. Based on recent news, 1. On March 16, the Hong Kong stock market experienced overall fluctuations and adjustments due to geopolitical conflicts. Southbound funds continued to flow in, but market sentiment remained cautious, leading to a decline in BeiGene's stock price. 2. On March 15, companies on the STAR Market saw overall revenue growth and reduced losses, with some leading innovative drug companies achieving profitability. However, fund managers remained cautious about the impact of AI technology on the pharmaceutical industry, affecting market confidence in BeiGene. 3. On March 17, the power equipment industry welcomed new development opportunities, attracting more investor attention and diversifying investments away from the pharmaceutical and biotechnology sector, indirectly impacting BeiGene's stock price. The Hong Kong stock market is highly volatile, with significant support from southbound funds ### Related Stocks - [02627.HK](https://longbridge.com/en/quote/02627.HK.md) ## Related News & Research - [Ab&B Bio-Tech Calls 2026 EGM to Overhaul Governance and Appoint New Auditor](https://longbridge.com/en/news/285581318.md) - [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md) - [Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement](https://longbridge.com/en/news/286834766.md) - [13:19 ETHyosung TNC Marks a Major Step in its Integrated Bio-Spandex Platform at Global Fashion Summit 2026](https://longbridge.com/en/news/286296991.md) - [04:00 ETScantox actualiza la bioinformática DuplexSeq™ con una aplicación de mutagénesis basada en la nube](https://longbridge.com/en/news/286057437.md)